{"id":10661,"date":"2021-08-03T10:34:38","date_gmt":"2021-08-03T08:34:38","guid":{"rendered":"https:\/\/www.nicox.com\/portefeuille-de-therapeutiques-ophtalmiques\/"},"modified":"2026-02-24T08:36:33","modified_gmt":"2026-02-24T06:36:33","slug":"portefeuille-de-therapeutiques-ophtalmiques","status":"publish","type":"page","link":"https:\/\/www.nicox.com\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/","title":{"rendered":"Portefeuille et domaines th\u00e9rapeutiques"},"content":{"rendered":"\n<div class=\"c-page-title c-wrapper\">\n\n    <div class=\"[ c-container ] [ u-align-center ]\" data-variant=\"narrow-column\">\n    \n        <h1 class=\"[ c-page-title__text ] [ u-text-base sm:u-text-plus-1 u-weight-bold ] [  ]\">\n\n            Portefeuille et domaines th\u00e9rapeutiques\n            \n        <\/h1>\n\n        <hr class=\"[ c-page-title__hr ] [ u-color-blue-4 ]\">\n    \n    <\/div>\n\n<\/div>\n\n\n<section class=\"[ c-wrapper c-pipeline ] [ u-vertical-padding ] [  ]\">\n\n    <div class=\"c-block-anchor\" id=\"block_673caa24e6c2d625c9cd11f57fccf800\"><\/div>\n\n    <div class=\"c-container\">\n\n        \n            <h2 class=\"u-caps u-text-plus-1 u-color-tan-2 u-weight-bold\">\n                Le portefeuille innovant de Nicox \n            <\/h2>\n\n        \n        \n            <h3 class=\"u-gap-top-base u-text-minus-1 u-weight-normal\">\n                NCX 470, un candidat m\u00e9dicament d\u00e9j\u00e0 valid\u00e9 et au potentiel mondial\n            <\/h3>\n\n        \n        <div class=\"[ c-pipeline__container ] [ u-gap-top-base ]\" >\n    \n                <div class=\"c-pipeline__table-head\">\n\n                    <div class=\"c-pipeline-th__title\"><\/div>\n                    <div class=\"c-pipeline-th__domain\"><\/div>\n                \n                    <div class=\"[ u-hide-small ] c-pipeline-th__phases\">\n\n                                                    <div Class=\"[ u-hide-small u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Stade Pr\u00e9-clinique <\/div>\n                                                    <div Class=\"[ u-hide-small u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Clinique <\/div>\n                                                    <div Class=\"[ u-hide-small u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  NDA <\/div>\n                                                    <div Class=\"[ u-hide-small u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Commercialis\u00e9 <\/div>\n                        \n                     <\/div>\n                                \n                    \n                    <div class=\"[ c-pipeline__th ] [ u-hide-small u-text-threequarter u-caps u-weight-normal u-align-center ] c-pipeline-th__partner\" style=\"color:#235295;\" >\n                        Partenaires\n                     <\/div>\n\n                 <\/div>               \n                            \n\n                        \n\n\n                \n                    <div class=\"c-pipeline__candidate-item\">\n\n                                \n                                    <div class=\"[ c-pipeline__td ] c-pipeline-th__title\" >\n                                                                                    <a class=\"[ c-pipeline__candidate-name ] [ u-text-threequarter sm:u-text-minus-2 lg:u-text-minus-2 xl:u-text-minus-1 ]\" href=\"\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/#product-vyzulta\">\n                                                                                    VYZULTA\u00ae\n                                                                                    <\/a>\n                                                                                                                        <span class=\"[ c-pipeline__candidate-product_note ] [ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\">Sol. Ophtalmologique de Latanoprostene Bunod 0.024%<\/span> \n                                        \n                                    \n                                     <\/div>\n                                    <div class=\"[ c-pipeline__td ] c-pipeline-th__domain\" >\n                                                                                <span class=\"[ c-pipeline__candidate-domain ] [ u-text-threequarter sm:u-text-minus-2 lg:u-text-minus-2 xl:u-text-minus-2 ]\">Glaucome et Hypertension oculaire <\/span>\n                                                                            <\/div>\n                                 \n\n                                    <div class=\"[ u-show-small ] c-pipeline-th__phases\">\n\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Stade Pr\u00e9-clinique <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Clinique <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  NDA <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Commercialis\u00e9 <\/div>\n                                        \n                                    <\/div>\n                                   \n\n                                    <div class=\"c-pipeline__phases-chart-item\" >\n\n                                                                                \n                                            <div class=\"c-pipeline__chart-bar\" style=\"width: 90%; background-color: #003366; \">\n                                                <span class=\"c-pipeline__chart-cap\"><\/span>\n                                                                                                <\/div>\n                                        \n                                        \n                                    <\/div>\n\n                                    \n                                    \n                                        <div class=\"c-pipeline__partner-item\" >\n                                                                                        \n                                                <div class=\" pipeline-inner-table \" style=\"width:55%\">\n                                                                                                        <img decoding=\"async\"  style=\" padding: 5px 15px\" src=\"https:\/\/www.nicox.com\/wp-content\/uploads\/bausch-lomb-e1756909953523.png\" alt=\"\">\n                                                                                                    <\/div>\n\n                                                <div class=\" pipeline-inner-table \"  style=\"width:45%; line-height:1\">\n                                                                                                        <span class=\"[ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\"  >Au niveau mondial<\/span>\n                                                                                                \n                                                <\/div>\n                                            \n                                                                                    <\/div>\n                                   \n                                    \n\n\n                                \n                                \n                     <\/div>\n\n                 \n                    <div class=\"c-pipeline__candidate-item\">\n\n                                \n                                    <div class=\"[ c-pipeline__td ] c-pipeline-th__title\" >\n                                                                                    <a class=\"[ c-pipeline__candidate-name ] [ u-text-threequarter sm:u-text-minus-2 lg:u-text-minus-2 xl:u-text-minus-1 ]\" href=\"\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/#product-zerviate\">\n                                                                                    ZERVIATE\u00ae\n                                                                                    <\/a>\n                                                                                                                        <span class=\"[ c-pipeline__candidate-product_note ] [ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\">Sol. Ophtalmologique de Cetirizine 0.24%<\/span> \n                                        \n                                    \n                                     <\/div>\n                                    <div class=\"[ c-pipeline__td ] c-pipeline-th__domain\" >\n                                                                                <span class=\"[ c-pipeline__candidate-domain ] [ u-text-threequarter sm:u-text-minus-2 lg:u-text-minus-2 xl:u-text-minus-2 ]\">Conjonctivites allergiques <\/span>\n                                                                            <\/div>\n                                 \n\n                                    <div class=\"[ u-show-small ] c-pipeline-th__phases\">\n\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Stade Pr\u00e9-clinique <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Clinique <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  NDA <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Commercialis\u00e9 <\/div>\n                                        \n                                    <\/div>\n                                   \n\n                                    <div class=\"c-pipeline__phases-chart-item\" >\n\n                                                                                \n                                            <div class=\"c-pipeline__chart-bar\" style=\"width: 90%; background-color: #003366; \">\n                                                <span class=\"c-pipeline__chart-cap\"><\/span>\n                                                                                                <\/div>\n                                        \n                                        \n                                    <\/div>\n\n                                    \n                                    \n                                        <div class=\"c-pipeline__partner-item\" >\n                                                                                        \n                                                <div class=\" pipeline-inner-table \" style=\"width:55%\">\n                                                                                                        <img decoding=\"async\"  style=\" padding: 5px 15px\" src=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Harrow_logo_wTag.jpg\" alt=\"\">\n                                                                                                    <\/div>\n\n                                                <div class=\" pipeline-inner-table \"  style=\"width:45%; line-height:1\">\n                                                                                                        <span class=\"[ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\"  >Etats-Unis<\/span>\n                                                                                                \n                                                <\/div>\n                                            \n                                                                                        \n                                                <div class=\" pipeline-inner-table \" style=\"width:55%\">\n                                                                                                        <img decoding=\"async\"  style=\" padding: 5px 15px\" src=\"https:\/\/www.nicox.com\/wp-content\/uploads\/ocumension-logo.webp\" alt=\"\">\n                                                                                                    <\/div>\n\n                                                <div class=\" pipeline-inner-table \"  style=\"width:45%; line-height:1\">\n                                                                                                        <span class=\"[ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\"  >Chine<\/span>\n                                                                                                \n                                                <\/div>\n                                            \n                                                                                    <\/div>\n                                   \n                                    \n\n\n                                \n                                \n                     <\/div>\n\n                 \n                    <div class=\"c-pipeline__candidate-item\">\n\n                                \n                                    <div class=\"[ c-pipeline__td ] c-pipeline-th__title\" >\n                                                                                    <a class=\"[ c-pipeline__candidate-name ] [ u-text-threequarter sm:u-text-minus-2 lg:u-text-minus-2 xl:u-text-minus-1 ]\" href=\"\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/#product-ncx-470\">\n                                                                                    NCX 470\n                                                                                    <\/a>\n                                                                                                                        <span class=\"[ c-pipeline__candidate-product_note ] [ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\">Sol. Ophtalmologique de Bimatoprost Grenod 0.1%<\/span> \n                                        \n                                    \n                                     <\/div>\n                                    <div class=\"[ c-pipeline__td ] c-pipeline-th__domain\" >\n                                                                                <span class=\"[ c-pipeline__candidate-domain ] [ u-text-threequarter sm:u-text-minus-2 lg:u-text-minus-2 xl:u-text-minus-2 ]\">Glaucome et Hypertension oculaire <\/span>\n                                                                            <\/div>\n                                 \n\n                                    <div class=\"[ u-show-small ] c-pipeline-th__phases\">\n\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Stade Pr\u00e9-clinique <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Clinique <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  NDA <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Commercialis\u00e9 <\/div>\n                                        \n                                    <\/div>\n                                   \n\n                                    <div class=\"c-pipeline__phases-chart-item\" >\n\n                                                                                \n                                            <div class=\"c-pipeline__chart-bar\" style=\"width: 66%; background-color: #003366; \">\n                                                <span class=\"c-pipeline__chart-cap\"><\/span>\n                                                                                                            <span class=\"c-pipeline__chart-note u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3\">\n                                                            Etats-Unis et Chine\n                                                        <\/span>\n                                                                                                <\/div>\n                                        \n                                                                                \n                                            <div class=\"c-pipeline__chart-bar\" style=\"width: 41%; background-color: #003366; \">\n                                                <span class=\"c-pipeline__chart-cap\"><\/span>\n                                                                                                            <span class=\"c-pipeline__chart-note u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3\">\n                                                            Japon\n                                                        <\/span>\n                                                                                                <\/div>\n                                        \n                                        \n                                    <\/div>\n\n                                    \n                                    \n                                        <div class=\"c-pipeline__partner-item\" >\n                                                                                        \n                                                <div class=\" pipeline-inner-table \" style=\"width:55%\">\n                                                                                                        <img decoding=\"async\"  style=\" padding: 5px 15px\" src=\"https:\/\/www.nicox.com\/wp-content\/uploads\/ocumension-logo.webp\" alt=\"\">\n                                                                                                    <\/div>\n\n                                                <div class=\" pipeline-inner-table \"  style=\"width:45%; line-height:1\">\n                                                                                                        <span class=\"[ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\"  >Chine, Cor\u00e9e et Asie du sud-est<\/span>\n                                                                                                \n                                                <\/div>\n                                            \n                                                                                        \n                                                <div class=\" pipeline-inner-table \" style=\"width:55%\">\n                                                                                                        <img decoding=\"async\"  style=\" padding: 5px 15px\" src=\"https:\/\/www.nicox.com\/wp-content\/uploads\/kowa_mark_red_RGB.webp\" alt=\"\">\n                                                                                                    <\/div>\n\n                                                <div class=\" pipeline-inner-table \"  style=\"width:45%; line-height:1\">\n                                                                                                        <span class=\"[ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\"  >Etats-Unis et l&rsquo;ensemble des autres territoires<\/span>\n                                                                                                \n                                                <\/div>\n                                            \n                                                                                    <\/div>\n                                   \n                                    \n\n\n                                \n                                \n                     <\/div>\n\n                 \n                    <div class=\"c-pipeline__candidate-item\">\n\n                                \n                                    <div class=\"[ c-pipeline__td ] c-pipeline-th__title\" >\n                                                                                    <a class=\"[ c-pipeline__candidate-name ] [ u-text-threequarter sm:u-text-minus-2 lg:u-text-minus-2 xl:u-text-minus-1 ]\" href=\"\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/#product-ncx-1728\">\n                                                                                    NCX 1728\n                                                                                    <\/a>\n                                                                                                                        <span class=\"[ c-pipeline__candidate-product_note ] [ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\">Inhibiteur de PDE-5 donneur de NO<\/span> \n                                        \n                                    \n                                     <\/div>\n                                    <div class=\"[ c-pipeline__td ] c-pipeline-th__domain\" >\n                                                                                <span class=\"[ c-pipeline__candidate-domain ] [ u-text-threequarter sm:u-text-minus-2 lg:u-text-minus-2 xl:u-text-minus-2 ]\">Glaucome (incl. neuroprotect.) Maladies de la r\u00e9tine <\/span>\n                                                                            <\/div>\n                                 \n\n                                    <div class=\"[ u-show-small ] c-pipeline-th__phases\">\n\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Stade Pr\u00e9-clinique <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Clinique <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  NDA <\/div>\n                                                                                    <div Class=\"[ u-text-threequarter u-caps u-weight-normal u-align-center] c-pipeline-th__phases-item\" >  Commercialis\u00e9 <\/div>\n                                        \n                                    <\/div>\n                                   \n\n                                    <div class=\"c-pipeline__phases-chart-item\" >\n\n                                                                                \n                                            <div class=\"c-pipeline__chart-bar\" style=\"width: 21%; background-color: #003366; \">\n                                                <span class=\"c-pipeline__chart-cap\"><\/span>\n                                                                                                <\/div>\n                                        \n                                        \n                                    <\/div>\n\n                                    \n                                    \n                                        <div class=\"c-pipeline__partner-item\" >\n                                                                                        \n                                                <div class=\" pipeline-inner-table \" style=\"width:55%\">\n                                                                                                        <img decoding=\"async\"  style=\" padding: 5px 15px\" src=\"https:\/\/www.nicox.com\/wp-content\/uploads\/glaukos-corporate-logo.jpg\" alt=\"\">\n                                                                                                    <\/div>\n\n                                                <div class=\" pipeline-inner-table \"  style=\"width:45%; line-height:1\">\n                                                                                                        <span class=\"[ u-text-threequarter sm:u-text-minus-3 lg:u-text-minus-3 xl:u-text-minus-3 ]\"  >Contrat de recherche avec option de licence mondiale<\/span>\n                                                                                                \n                                                <\/div>\n                                            \n                                                                                    <\/div>\n                                   \n                                    \n\n\n                                \n                                \n                     <\/div>\n\n                 \n         <\/div>\n\n\n     <\/div>\n\n<\/section>\n\n\n<section class=\"[ c-portfolio c-wrapper ] [  u-bg-blue-1 ]\">\n\n    <div class=\"c-block-anchor\" id=\"domaines-therapeutiques-cibles\"><\/div>\n\n    <div class=\"c-container\">\n\n        \n            <h2 class=\"[ c-portfolio__title ] [ u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                Domaines th\u00e9rapeutiques cibl\u00e9s\n            <\/h2>\n\n        \n        \n    <\/div>\n\n    \n        <div class=\"c-portfolio__container\">\n    \n            \n        <\/div>\n\n        <div class=\"c-portfolio__grid-container\">\n\n            <div class=\"c-portfolio__grid\">\n\n                                \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-glaucome\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            Glaucome\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            Une cause majeure de c\u00e9cit\u00e9\n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            Le glaucome est une maladie du nerf optique qui, si elle n\u2019est pas trait\u00e9e, peut entra\u00eener une perte irr\u00e9versible de la vision. \n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"glaucome\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"glaucome\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"glaucome\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"glaucome\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            Glaucome<br>\n                                        \n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                    \n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>Le glaucome est une maladie du nerf optique qui, si elle n\u2019est pas trait\u00e9e, peut entra\u00eener une perte irr\u00e9versible de la vision. Le glaucome est actuellement consid\u00e9r\u00e9 comme l\u2019une des trois principales causes de c\u00e9cit\u00e9 irr\u00e9versible dans le monde. Le glaucome est fr\u00e9quemment li\u00e9 \u00e0 une pression intraoculaire \u00e9lev\u00e9e (PIO) et est souvent d\u00fb \u00e0 une obstruction du syst\u00e8me de drainage de l\u2019humeur aqueuse situ\u00e9 dans la partie ant\u00e9rieure de l\u2019\u0153il. Cette augmentation de la pression peut endommager le nerf optique. Actuellement, la r\u00e9duction de la pression intraoculaire est le seul moyen de ralentir la progression de la maladie. Le glaucome affecte des millions de patients.\u00a0Il est estim\u00e9 qu\u2019environ 3,5% de la population mondiale\u00a0\u00e2g\u00e9e de 40 \u00e0 80 ans est touch\u00e9e par la forme la plus courante de glaucome.<\/p>\n<p>Les traitements actuels visent \u00e0 r\u00e9duire la PIO dans le but de ralentir la progression de la maladie. Il est g\u00e9n\u00e9ralement admis que chaque mmHg de r\u00e9duction de la PIO entra\u00eene une diminution du risque de progression du glaucome \u00e0 angle ouvert d\u2019environ 10%. De nombreux collyres sont disponibles, soit pour diminuer la quantit\u00e9 de fluide produite par l\u2019\u0153il, soit pour am\u00e9liorer son \u00e9coulement hors de l\u2019\u0153il. 40\u00a0% des patients n\u2019atteignent pas la PIO au niveau de pression souhait\u00e9 avec les monoth\u00e9rapies existantes, ce qui risque de faire progresser la maladie et de perdre la vue. Malgr\u00e9 l\u2019existence de th\u00e9rapies de premi\u00e8res lignes, incluant le traitement de r\u00e9f\u00e9rence, latanoprost, il subsiste un besoin m\u00e9dical non satisfait pour une th\u00e9rapie offrant une efficacit\u00e9 sup\u00e9rieure dans la r\u00e9duction de la PIO qui soit \u00e0 la fois s\u00fbre et bien tol\u00e9r\u00e9e.<\/p>\n<p>Un autre domaine de recherche consiste \u00e0 d\u00e9velopper des produits capables de prot\u00e9ger le fond de l\u2019\u0153il (la r\u00e9tine), o\u00f9 se situe le nerf optique, contre les dommages associ\u00e9s \u00e0 l\u2019augmentation de la pression intraoculaire, ce que l\u2019on appelle la \u00ab\u00a0neuroprotection\u00a0\u00bb.<\/p>\n<p>Le glaucome touche des millions de patients \u00e0 travers le monde.<\/p>\n<div class=\"c-container\">\n<div class=\"[ c-offset-stats__grid ]\">\n<article class=\"[ c-offset-stats__block ]\" data-slide-in=\"\">80 millions<\/p>\n<h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">Population atteinte du glaucome<\/h3>\n<div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">\n<p>On estime qu\u2019environ 80 millions de personnes sont touch\u00e9es par la forme la plus courante du glaucome.<\/p>\n<\/div>\n<\/article>\n<article class=\"[ c-offset-stats__block ]\" data-slide-in=\"\"><span class=\"[ c-offset-stats__block-stat ]\"> 50% <\/span><\/p>\n<h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">Non diagnostiqu\u00e9s<\/h3>\n<div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">\n<p>Le glaucome \u00e0 angle ouvert, la forme la plus courante du glaucome, est souvent associ\u00e9 \u00e0 une augmentation de la pression oculaire. Il n\u2019y a de sympt\u00f4mes pr\u00e9coces, c\u2019est pourquoi 50 % des personnes atteintes de glaucome ne savent pas qu\u2019elles ont cette maladie.<\/p>\n<\/div>\n<\/article>\n<article class=\"[ c-offset-stats__block ]\" data-slide-in=\"\">7 milliards de dollars<\/p>\n<h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">March\u00e9 mondial<\/h3>\n<div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">\n<p>7 milliards de dollars, pouvant atteindre 3% \u00e0 5% CAGR (Compound Annual Gross Rate)<\/p>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-conjonctivite-allergique\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            Conjonctivite allergique\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            Une des pathologies les plus courantes de l\u2019oeil\n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            La conjonctivite allergique se produit lorsqu\u2019une r\u00e9action allergique provoque une conjonctivite, une inflammation de la fine couche de tissu qui recouvre la surface ext\u00e9rieure blanche de l\u2019\u0153il et la surface interne des paupi\u00e8res.\n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"conjonctivite-allergique\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"conjonctivite-allergique\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"conjonctivite-allergique\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"conjonctivite-allergique\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            Conjonctivite allergique<br>\n                                        \n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                    \n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>La conjonctivite allergique se produit lorsqu\u2019une r\u00e9action allergique provoque une conjonctivite, une inflammation de la fine couche de tissu qui recouvre la surface ext\u00e9rieure blanche de l\u2019\u0153il et la surface interne des paupi\u00e8res. La conjonctivite peut affecter un \u0153il ou les deux yeux. Les signes et les sympt\u00f4mes peuvent inclure rougeurs de l\u2019\u0153il, larmoiements excessifs, br\u00fblures et d\u00e9mangeaisons oculaires, \u00e9coulements d\u2019aspect purulent, vision floue et sensibilit\u00e9 accrue \u00e0 la lumi\u00e8re. Aux \u00c9tats-Unis, il est estim\u00e9 que plus de 75 millions de personnes souffriraient de conjonctivite allergique et la pr\u00e9valence de la conjonctivite allergique se situerait entre 15% et 40%.<\/p>\n<div class=\"[ c-call-to-action__section-one ] [ u-flow u-links-reversed ]\" data-variant=\"media\"><img decoding=\"async\" class=\"[ c-call-to-action__image ] u-bg-image lazy loaded\" src=\"\/wp-content\/uploads\/main_928px.jpg\" alt=\"\" data-src=\"\/wp-content\/uploads\/main_928px.jpg\" data-was-processed=\"true\" \/><\/div>\n<p>&nbsp;<\/p>\n<div class=\"u-text-minus-2 sm:u-text-base\">\n<p>La conjonctivite allergique est courante chez les personnes qui pr\u00e9sentent d\u2019autres signes d\u2019allergie, tels que le rhume des foins, l\u2019asthme et l\u2019ecz\u00e9ma. Elle est caus\u00e9e par la r\u00e9action du corps \u00e0 certaines substances auxquelles il est allergique.<\/p>\n<\/div>\n<div class=\"c-container\">\n<div class=\"[ c-offset-stats__grid ]\">\n<article class=\"[ c-offset-stats__block ]\" data-slide-in=\"\"><span class=\"[ c-offset-stats__block-stat ] [ u-text-plus-4 u-weight-light ]\" > 75 millions <\/span><\/p>\n<h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">Personnes souffrant de conjonctivite allergique<\/h3>\n<div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">On estime que plus de 75 millions de personnes souffriraient de conjonctivite allergique aux \u00c9tats-Unis.<\/div>\n<\/article>\n<article class=\"[ c-offset-stats__block ]\" data-slide-in=\"\"><span class=\"[ c-offset-stats__block-stat ] [ u-text-plus-4 u-weight-light ]\"> 40% <\/span><\/p>\n<h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">Incidence de la conjonctivite allergique<\/h3>\n<div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">Parmi ces personnes souffrant de conjonctivite allergique aux \u00c9tats-Unis, l\u2019incidence de la conjonctivite allergique se situerait entre 15% et 40%.<\/div>\n<\/article>\n<\/div>\n<\/div>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-affections-de-la-retine\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            Affections de la r\u00e9tine\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            \n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            La r\u00e9tine est une fine couche sensible \u00e0 la lumi\u00e8re situ\u00e9e dans le fond de l\u2019\u0153il, qui transforme la lumi\u00e8re entrante en signaux \u00e9lectriques que le cerveau peut interpr\u00e9ter comme de la vision. Lorsque des maladies touchent la r\u00e9tine, ce processus est perturb\u00e9, entra\u00eenant souvent une diminution de la vision, pouvant aller jusqu\u2019\u00e0 la c\u00e9cit\u00e9. \n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"affections-de-la-retine\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"affections-de-la-retine\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"affections-de-la-retine\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"affections-de-la-retine\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            Affections de la r\u00e9tine<br>\n                                        \n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                    \n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>La r\u00e9tine est une fine couche sensible \u00e0 la lumi\u00e8re situ\u00e9e dans le fond de l\u2019\u0153il, qui transforme la lumi\u00e8re entrante en signaux \u00e9lectriques que le cerveau peut interpr\u00e9ter comme de la vision. Lorsque des maladies touchent la r\u00e9tine, ce processus est perturb\u00e9, entra\u00eenant souvent une diminution de la vision, pouvant aller jusqu\u2019\u00e0 la c\u00e9cit\u00e9. L\u2019un des exemples les plus courants est la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge (DMLA), qui endommage la macula, la partie centrale de la r\u00e9tine responsable de la vision nette. La DMLA se pr\u00e9sente sous deux formes\u00a0: la forme s\u00e8che, qui \u00e9volue progressivement avec un amincissement de la macula et l\u2019accumulation de petits d\u00e9p\u00f4ts de d\u00e9chets appel\u00e9s drusen, et la forme humide, moins fr\u00e9quente mais beaucoup plus agressive, en raison de vaisseaux sanguins anormaux qui fuient et endommagent les tissus r\u00e9tiniens.<\/p>\n<p>Une autre affection r\u00e9pandue est la r\u00e9tinopathie diab\u00e9tique, une complication du diab\u00e8te de longue dur\u00e9e qui endommage les vaisseaux sanguins de la r\u00e9tine et reste l\u2019une des principales causes mondiales de perte de la vision.<\/p>\n<p>Certaines affections sont beaucoup plus rares, comme la r\u00e9tinite pigmentaire, un trouble h\u00e9r\u00e9ditaire touchant environ une personne sur 4 000, qui entra\u00eene une diminution progressive du champ visuel au fil du temps.<\/p>\n<p>Ensemble, ces maladies illustrent clairement l\u2019urgence du besoin clinique et ouvrent des perspectives uniques pour le traitement des affections r\u00e9tiniennes.<\/p>\n<div class=\"c-container\">\n<div class=\"[ c-offset-stats__grid ]\">\n<article class=\"[ c-offset-stats__block ]\" data-slide-in=\"\">200 millions<\/p>\n<h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">Patients souffrant de DMLA<\/h3>\n<div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">\n<p>            Selon les estimations, environ 200 millions de personnes sont concern\u00e9es par la  DMLA.<\/p><\/div>\n<\/article>\n<article class=\"[ c-offset-stats__block ]\">\n        100 millions<\/p>\n<h3 class=\"[ c-offset-stats__block-title ] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">Patients souffrant de r\u00e9tinopathie diab\u00e9tique<\/h3>\n<div class=\"[ c-offset-stats__block-content ] [ u-gap-top-quarter u-text-minus-2 ]\">\n            Environ 100 millions de personnes sont estim\u00e9es souffrir de r\u00e9tinopathie diab\u00e9tique.\n        <\/div>\n<\/article>\n<\/div>\n<\/div>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n            <\/div>\n\n        <\/div>\n    \n    \n<\/section>\n\n\n<section class=\"[ c-portfolio c-wrapper ] [  ]\">\n\n    <div class=\"c-block-anchor\" id=\"portfolio\"><\/div>\n\n    <div class=\"c-container\">\n\n        \n            <h2 class=\"[ c-portfolio__title ] [ u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                Notre portefeuille\n            <\/h2>\n\n        \n        \n    <\/div>\n\n    \n        <div class=\"c-portfolio__container\">\n    \n            \n                <h3 class=\"[ c-portfolio__section-heading ] [ u-gap-top-plus-3 u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\" style=\"color: #b7b494;\">\n                    Candidats m\u00e9dicaments\n                <\/h3>\n            \n            \n        <\/div>\n\n        <div class=\"c-portfolio__grid-container\">\n\n            <div class=\"c-portfolio__grid\">\n\n                                \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-ncx-470\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            NCX 470\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            Principal candidat m\u00e9dicament en d\u00e9veloppement clinique de Nicox\n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            NCX 470 est un nouveau collyre bimatoprost donneur d\u2019oxyde nitrique (NO), en d\u00e9veloppement clinique pour la r\u00e9duction de la pression intraoculaire (PIO) chez des patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire. Deux essais cliniques de Phase 3 ont \u00e9t\u00e9 achev\u00e9s avec succ\u00e8s et des demandes d\u2019autorisation de mise sur le march\u00e9 sont en cours de pr\u00e9paration aux \u00c9tats-Unis et en Chine, tandis qu\u2019un programme distinct de Phase 3 est en cours au Japon.\n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"ncx-470\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"ncx-470\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"ncx-470\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"ncx-470\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            NCX 470<br>\n                                        \n                                                                                            <div class=\"u-gap-top-quarter u-color-grey-2 u-text-minus-1 sm:u-text-base u-weight-light u-leading-base\">\n                                                    <span class=\"u-color-white\" aria-hidden=\"true\"> Statut :<\/span> \n                                                    <p><strong>Etude de phase 3 Mont Blanc et Denali achev\u00e9es &#8211;<\/strong><strong>Etude de phase 3b Whistler achev\u00e9e<\/strong><\/p>\n<p><strong>Contrat de licence exclusif avec Kowa pour le d\u00e9veloppement et la commercialisation du NCX 470 dans l&rsquo;ensemble des territoires du monde en dehors de la Chine, de la Cor\u00e9e et de l&rsquo;Asie du Sud-Est o\u00f9 NCX 470 est licenci\u00e9 \u00e0 Ocumension.<\/strong><\/p>\n<p><strong>Etudes cliniques de Phase 3 en cours au Japon.<\/strong><\/p>\n\n                                                <\/div>\n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                                                        \n                                        <h3 class=\"[ c-portfolio__milestone-title ] [ u-gap-top-minus-2 sm:u-gap-top-base u-text-minus-2 u-weight-bold ]\">\n                                            Etapes attendues : \n                                        <\/h3>\n\n                                    \n                                                                        \n                                        <ul>\n                                                                                            <li>Demandes d&rsquo;autorisation de mise sur le march\u00e9 en cours de pr\u00e9paration aux \u00c9tats-Unis et en Chine <\/li>\n                                                                                    <\/ul>\n\n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>NCX 470 est un nouveau collyre bimatoprost donneur d\u2019oxyde nitrique (NO) qui utilise les puissants effets de r\u00e9duction de la pression intraoculaire (PIO) de l\u2019oxyde nitrique (NO) et des analogues de prostaglandine (PGAs). NCX 470 conjugue la plateforme de recherche de Nicox de compos\u00e9s donneurs de NO et le bimatoprost dans une seule mol\u00e9cule. NCX 470 est con\u00e7u pour lib\u00e9rer du bimatoprost et du NO dans l\u2019\u0153il afin de r\u00e9duire la PIO par le biais de deux voies de drainage chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire. Le NO est une petite mol\u00e9cule messager naturelle, bien connue, qui joue un r\u00f4le cl\u00e9 dans la r\u00e9gulation de la PIO au travers de l\u2019activation de la Guanylate Cyclase soluble (GCs). L\u2019oxyde nitrique apporte une efficacit\u00e9 de r\u00e9duction de la PIO suppl\u00e9mentaire en am\u00e9liorant le drainage de l\u2019humeur aqueuse de l\u2019\u0153il via un m\u00e9canisme d\u2019action diff\u00e9rent de celui des analogues de prostaglandine. Le bimatoprost, commercialis\u00e9 sous le nom de sp\u00e9cialit\u00e9 Lumigan\u00ae par AbbVie, Inc., est le principal produit de sp\u00e9cialit\u00e9 de la classe des analogues de prostaglandine. Les analogues de prostaglandine sont la classe des m\u00e9dicaments la plus couramment utilis\u00e9e pour la r\u00e9duction de la PIO chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire.<\/p>\n<p>NCX 470 a achev\u00e9 deux essais cliniques de Phase 3 con\u00e7us pour r\u00e9pondre aux exigences r\u00e9glementaires en mati\u00e8re de s\u00e9curit\u00e9 et d\u2019efficacit\u00e9, en vue de soutenir les demandes d\u2019Autorisation de Mise sur le March\u00e9 (NDA) aux \u00c9tats-Unis et en Chine, <a href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/FR-_NCX-470-MontBlanc-Phase-3-Topline-results-PR_V20221031_F.pdf\">Mont Blanc<\/a> et <a href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/FR_NCX470DenaliToplineAugust2025_PR_FINAL.pdf\">Denali<\/a>. Les deux essais ont donn\u00e9 des r\u00e9sultats positifs et atteint les crit\u00e8res d\u2019efficacit\u00e9 requis pour le d\u00e9p\u00f4t d\u2019une demande d\u2019autorisation de mise sur le march\u00e9 aux \u00c9tats-Unis et en Chine.<\/p>\n<p>NCX 470 a \u00e9galement fait l\u2019objet d\u2019une \u00e9tude de Phase 2, <a href=\"https:\/\/journals.lww.com\/glaucomajournal\/fulltext\/2022\/06000\/a_randomized,_controlled_comparison_of_ncx_470.3.aspx\">Dolomites<\/a>, ainsi que dans un essai de Phase 3b, <a href=\"https:\/\/www.nicox.com\/fr\/actualites-et-evenements\/communiques-de-presse\/#:~:text=Nicox%20annonce%20les%20r%C3%A9sultats%20de%20l%E2%80%99%C3%A9tude%20exploratoire%20de%20phase%203b%20Whistler%20dans%20le%20glaucome\">Whistler<\/a>, et un programme distinct de Phase 3 est en cours au Japon<\/p>\n<p>Des \u00e9tudes non cliniques exploratoires dans un mod\u00e8le bien d\u00e9fini de l\u00e9sions de la t\u00eate du nerf optique et de la r\u00e9tine (isch\u00e9mie\/reperfusion induites par l&rsquo;ET-1) ont \u00e9tudi\u00e9 les effets du NCX 470 au-del\u00e0 de ses propri\u00e9t\u00e9s de r\u00e9duction de la PIO. Les r\u00e9sultats sugg\u00e8rent que le NCX 470 am\u00e9liore la perfusion oculaire et la fonction r\u00e9tinienne dans les yeux endommag\u00e9s par rapport au v\u00e9hicule et au Lumigan<sup>\u00ae <\/sup>et pourrait donc avoir des propri\u00e9t\u00e9s protectrices pour la r\u00e9tine. <strong>\u00a0<\/strong>Les effets b\u00e9n\u00e9fiques de NCX 470 ont \u00e9galement \u00e9t\u00e9 d\u00e9montr\u00e9s dans un mod\u00e8le in vivo de l\u00e9sion des cellules r\u00e9tiniennes (voir <a href=\"https:\/\/www.nicox.com\/fr\/actualites-et-evenements\/communiques-de-presse\/#:~:text=Nicox%20%3A%20Protection%20des%20cellules%20r%C3%A9tiniennes%20par%20le%20NCX%20470%20montr%C3%A9e%20dans%20un%20mod%C3%A8le%20non%20clinique\">communiqu\u00e9 de presse du 29 septembre 2021<\/a>).<\/p>\n<p>NCX 470 est prot\u00e9g\u00e9 au niveau mondial par des brevets couvrant la composition de mati\u00e8re jusqu\u2019en 2029, avec une potentielle extension de la dur\u00e9e de la protection pouvant atteindre 5 ans aux Etats-Unis et en Europe, et par des brevets portant sur la formulation jusqu\u2019en 2039 aux Etats-Unis, en Europe, au Japon et en Chine et dans d\u2019autres territoires.<\/p>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-ncx-1728\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            NCX 1728\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            Premier compos\u00e9 d\u2019une nouvelle classe de mol\u00e9cules donneuses de NO\n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            NCX 1728 est un inhibiteur de la phosphodiest\u00e9rase 5 (PDE-5) donneur de NO actuellement en recherche pr\u00e9clinique avec un potentiel de d\u00e9veloppement dans le traitement du glaucome, y compris la neuroprotection, ainsi que dans les maladies de la r\u00e9tine.\n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"ncx-1728\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"ncx-1728\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"ncx-1728\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"ncx-1728\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            NCX 1728<br>\n                                        \n                                                                                            <div class=\"u-gap-top-quarter u-color-grey-2 u-text-minus-1 sm:u-text-base u-weight-light u-leading-base\">\n                                                    <span class=\"u-color-white\" aria-hidden=\"true\"> Statut :<\/span> \n                                                    <p><strong>Evaluation pr\u00e9clinique<br \/>\n<\/strong><\/p>\n\n                                                <\/div>\n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                                                        \n                                        <h3 class=\"[ c-portfolio__milestone-title ] [ u-gap-top-minus-2 sm:u-gap-top-base u-text-minus-2 u-weight-bold ]\">\n                                            Etapes attendues : \n                                        <\/h3>\n\n                                    \n                                                                        \n                                        <ul>\n                                                                                            <li>Exercice potentiel de l\u2019option de licence mondiale dans le cadre de l\u2019accord exclusif de recherche avec Glaukos<\/li>\n                                                                                    <\/ul>\n\n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>NCX 1728, un inhibiteur de la phosphodiest\u00e9rase 5 (PDE-5) donneur de NO, est le premier compos\u00e9 d\u2019une nouvelle classe de mol\u00e9cules donneuses de NO dans laquelle les effets modul\u00e9s par le NO sont renforc\u00e9s et prolong\u00e9s par l\u2019action concomitante, dans la m\u00eame mol\u00e9cule, de l\u2019activit\u00e9 inhibitrice de la PDE-5. Il a \u00e9t\u00e9 d\u00e9montr\u00e9 que l\u2019inhibition de la PDE-5 renforce l\u2019efficacit\u00e9 et la dur\u00e9e des effets modul\u00e9s par le NO. Cette classe de mol\u00e9cules a le potentiel d\u2019\u00eatre d\u00e9velopp\u00e9e dans le glaucome et dans des maladies de la r\u00e9tine et est actuellement en cours d\u2019\u00e9valuation dans le cadre d\u2019un accord exclusif de recherche incluant une option de licence mondiale avec Glaukos.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n            <\/div>\n\n        <\/div>\n    \n    \n        <div class=\"c-portfolio__container\">\n    \n            \n                <h3 class=\"[ c-portfolio__section-heading ] [ u-gap-top-plus-3 u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\" style=\"color: #b7b494;\">\n                    Produits commercialis\u00e9s \n                <\/h3>\n            \n            \n        <\/div>\n\n        <div class=\"c-portfolio__grid-container\">\n\n            <div class=\"c-portfolio__grid\">\n\n                                \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-vyzulta\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            VYZULTA<sup>\u00ae<\/sup>\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            Un analogue de prostaglandine, dont l\u2019un des m\u00e9tabolites est l\u2019oxyde nitrique (NO)\n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            VYZULTA<sup>\u00ae<\/sup> (solution ophtalmique de latanoprost\u00e8ne bunod), 0,024%, indiqu\u00e9 pour la r\u00e9duction de la pression intraoculaire (PIO) chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire,\r\n\r\nFait l\u2019objet d\u2019un accord de concession de licence exclusif mondial avec Bausch + Lomb, un leader mondial de la sant\u00e9 oculaire. VYZULTA est commercialis\u00e9 plus de 15 pays, dont les \u00c9tats-Unis, et est \u00e9galement approuv\u00e9 dans un certain nombre d&rsquo;autres pays. \r\n\r\n\r\n    Nicox a vendu les redevances de VYZULTA \u00e0 Soleus Capital en octobre 2024.\n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"vyzulta\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"vyzulta\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"vyzulta\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"vyzulta\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            VYZULTA<sup>\u00ae<\/sup><br>\n                                        \n                                                                                            <div class=\"u-gap-top-quarter u-color-grey-2 u-text-minus-1 sm:u-text-base u-weight-light u-leading-base\">\n                                                    <span class=\"u-color-white\" aria-hidden=\"true\"> Statut :<\/span> \n                                                    <p>Mis sur le march\u00e9 dans plus de 15 pays, dont les \u00c9tats-Unis.<\/p>\n\n                                                <\/div>\n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                                                        \n                                        <h3 class=\"[ c-portfolio__milestone-title ] [ u-gap-top-minus-2 sm:u-gap-top-base u-text-minus-2 u-weight-bold ]\">\n                                            Etapes attendues : \n                                        <\/h3>\n\n                                    \n                                                                        \n                                        <ul>\n                                                                                            <li>Revenus r\u00e9currents<\/li>\n                                                                                    <\/ul>\n\n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>VYZULTA, dont les droits mondiaux exclusifs ont \u00e9t\u00e9 accord\u00e9s \u00e0 Bausch + Lomb, est un analogue de prostaglandine, dont l\u2019un des m\u00e9tabolites est l\u2019oxyde nitrique (NO). VYZULTA est indiqu\u00e9 aux Etats-Unis pour la r\u00e9duction de la PIO chez les patients atteints de glaucome \u00e0 angle ouvert ou d\u2019hypertension oculaire. Lors de son approbation, VYZULTA \u00e9tait le premier collyre approuv\u00e9 au cours des 20 derni\u00e8res ann\u00e9es avec une nouvelle approche pour la r\u00e9duction de la PIO.<\/p>\n<p>VYZULTA a \u00e9t\u00e9 mis sur le march\u00e9 dans plus de 15 pays, dont les \u00c9tats-Unis, o\u00f9 il est prot\u00e9g\u00e9 par un brevet couvrant sa composition de mati\u00e8re jusqu\u2019en 2029.<\/p>\n<p>Nicox a vendu les redevances de VYZULTA \u00e0 Soleus Capital en octobre 2024.<\/p>\n<p>Plus d&rsquo;informations sur VYZULTA sur le site de notre partenaire\u00a0<a href=\"http:\/\/www.vyzulta.com\">http:\/\/www.vyzulta.com<\/a>\u00a0.<\/p>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n                    <article class=\"c-product\">\n\n                        <div class=\"c-block-anchor\" id=\"product-zerviate\"><\/div>\n\n                        <hr>\n                    \n                        <h4 class=\"[ c-product__title] [ u-gap-top-base u-text-base sm:u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                            ZERVIATE<sup>\u00ae<\/sup>\n                        <\/h4>\n                        \n                        <h5 class=\"[ c-product__type ] [ u-gap-top-plus-2 u-text-minus-2 u-weight-bold ]\">\n                            Indiqu\u00e9 pour le traitement du prurit oculaire associ\u00e9 aux conjonctivites allergiques\n                        <\/h5>\n                        \n                        <div class=\"[ c-product__excerpt ] [ u-gap-top-quarter u-text-minus-2 ]\">\n                            ZERVIATE\u00ae (solution ophtalmique de c\u00e9tirizine) 0,24%, indiqu\u00e9 pour le traitement du prurit oculaire associ\u00e9 aux conjonctivites allergiques, est commercialis\u00e9 aux Etats-Unis par le partenaire am\u00e9ricain Harrow et en Chine par Ocumension Therapeutics. Un accord de concession de licence exclusif a \u00e9t\u00e9 conclu avec Ocumension Therapeutics pour le d\u00e9veloppement et la commercialisation de ZERVIATE sur le march\u00e9 chinois et la majorit\u00e9 des march\u00e9s d\u2019Asie du Sud-Est. \n                        <\/div>\n                        \n                        <button class=\"[ c-icon-link c-product__readmore ] [ u-gap-top-threequarter u-text-minus-2 ]\" data-disclosure-toggle=\"zerviate\" data-open-details data-variant=\"medium\">\n                            <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                            <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                            <\/span>\n                        \n                        <\/button>\n\n                        <div class=\"[ c-wrapper c-detail c-portfolio__detail ]\" data-disclosure-target=\"zerviate\">\n\n                            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"zerviate\" data-close-details><\/button>\n\n                                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"zerviate\" data-close-details data-variant=\"medium\">\n\n                                        <span class=\"c-icon-link__text\">\n                                            Fermer\n                                        <\/span>\n\n                                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                                        <\/span>\n\n                                    <\/button>\n\n                                    \n                                        <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold u-leading-loose ]\">\n                                            ZERVIATE<sup>\u00ae<\/sup><br>\n                                        \n                                                                                            <div class=\"u-gap-top-quarter u-color-grey-2 u-text-minus-1 sm:u-text-base u-weight-light u-leading-base\">\n                                                    <span class=\"u-color-white\" aria-hidden=\"true\"> Statut :<\/span> \n                                                    <p>Commercialis\u00e9 aux Etats-Unis par le partenaire am\u00e9ricain Harrow et en Chine par Ocumension Therapeutics<\/p>\n<p>Partenariats aussi en Asie du Sud-Est et au Moyen Orient<\/p>\n\n                                                <\/div>\n                                                                                    <\/h2>\n\n                                    \n                                <\/header>\n\n                                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                                                                        \n                                        <h3 class=\"[ c-portfolio__milestone-title ] [ u-gap-top-minus-2 sm:u-gap-top-base u-text-minus-2 u-weight-bold ]\">\n                                            Etapes attendues : \n                                        <\/h3>\n\n                                    \n                                                                        \n                                        <ul>\n                                                                                            <li>Revenus r\u00e9currents<\/li>\n                                                                                    <\/ul>\n\n                                    \n                                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                                    <div class=\"u-color-grey-2\">\n\n                                        <p>ZERVIATE\u00ae est un collyre innovant et de formulation brevet\u00e9e de c\u00e9tirizine approuv\u00e9 aux Etats-Unis pour le traitement du prurit oculaire associ\u00e9 aux conjonctivites allergiques.<\/p>\n<p>ZERVIATE est commercialis\u00e9 aux \u00c9tats-Unis par le partenaire am\u00e9ricain exclusif Harrow, Inc. et en Chine par Ocumension Therapeutics.<\/p>\n<p>La formulation de ZERVIATE est prot\u00e9g\u00e9e par des brevets d\u00e9livr\u00e9s aux Etats-Unis jusqu\u2019en 2030 et 2032, et jusqu\u2019en 2030 en Europe, au Japon et au Canada.<\/p>\n<p>Plus d\u2019informations sur ZERVIATE aux Etats-Unis sur le site de notre partenaire <a href=\"https:\/\/www.zerviate.com\/\">https:\/\/www.zerviate.com<\/a><\/p>\n\n\n                                    <\/div>\n\n                                <\/div>\n\n                            <\/div>\n\n                        <\/div>\n                        \n                    <\/article>\n                    \n                \n            <\/div>\n\n        <\/div>\n    \n    \n<\/section>\n\n\n<section class=\"[ c-full-video ] [ u-color-white u-bg-blue-7  u-bg-black u-color-white ]\">\n\n    <div class=\"c-block-anchor\" id=\"block_8b52b0b680f3481da00a89567f8bbf15\"><\/div>\n\n    \n        <div class=\"[ c-video-content u-bg-cover ]\" style=\"background-image: url('https:\/\/i.vimeocdn.com\/video\/1181422467-25281d28c34e3980206b7a9e10351ab8bb16d5a778967d69990bea4d869a49de-d_640?region=us');\">\n\n            <lite-vimeo videoid=\"571214473\"><\/lite-vimeo>\n\n            \n                <span class=\"[ c-full-video__title ] [ u-text-plus-1 sm:u-text-plus-2 md:u-text-plus-3 lg:u-text-plus-4 u-weight-light ]\">Mode d\u2019action de notre science<\/span>\n\n            \n        <\/div>\n\n    \n\n<\/section>\n\n\n<section class=\"[ c-centered-column c-wrapper ] [ u-vertical-padding ] [   ]\">\n\n    <div class=\"c-block-anchor\" id=\"nitric-oxide-donation\"><\/div>\n\n    <div class=\"c-container\" data-variant=\"wide-column\">\n\n                    \n            <h2 class=\"[ c-centered-column__title ] [ u-text-plus-4 md:u-text-plus-5 lg:u-text-plus-6 u-weight-light ]\">\n                Lib\u00e9ration d&rsquo;oxyde nitrique\n            <\/h2>\n\n            \n    <\/div>\n\n    <div class=\"[ c-container ] [ c-text-content ]\" data-variant=\"narrow-column\">\n\n                    <h3 class=\"u-caps-heading\">\n                L\u2019expertise de Nicox\n            <\/h3>\n        \n                    <div class=\"u-gap-top-base\">\n                <p>Nous avons d\u00e9velopp\u00e9 une position strat\u00e9gique et scientifique de leader dans l\u2019application th\u00e9rapeutique de compos\u00e9s donneurs d\u2019oxyde nitrique (NO) dans le domaine de l\u2019ophtalmologie utilisant notre expertise exclusive dans le d\u00e9veloppement de nouvelles mol\u00e9cules brevetables qui lib\u00e8rent du NO, d\u00e9veloppant un portefeuille de brevets significatifs.<\/p>\n<p>Notre plateforme de recherche a produit des compos\u00e9s donneurs de NO ciblant le glaucome, notamment VYZULTA\u00ae, notre premier produit approuv\u00e9 par la FDA am\u00e9ricaine, commercialis\u00e9 aux Etats-Unis et dans d\u2019autres pays\u00a0par notre partenaire mondial exclusif, Bausch + Lomb, NCX 470, actuellement en phase 3 de d\u00e9veloppement clinique et NCX 1728, en \u00e9valuation pr\u00e9clinique avec Glaukos.<\/p>\n\n            <\/div>\n        \n        <button class=\"[ c-icon-link ] [ u-gap-top-base ]\" data-variant=\"medium\" data-disclosure-toggle=\"expertise-nitric-oxide-donation\" data-open-details>\n\n            <span class=\"c-icon-link__text\">\n                Plus d&rsquo;informations\n            <\/span>\n\n            <span class=\"c-icon c-icon-link__icon\">\n                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n            <\/span>\n\n        <\/button>\n\n        <div class=\"[ c-wrapper c-detail c-expertise__detail ]\" data-disclosure-target=\"expertise-nitric-oxide-donation\">\n\n            <div class=\"[ c-detail__content ] [ u-bg-blue-5 u-color-white ]\">\n\n                <header class=\"[ c-detail-header ] [ u-links-reversed ]\">\n\n                    <button class=\"c-detail__overlay\" data-disclosure-toggle=\"expertise-nitric-oxide-donation\" data-close-details><\/button>\n\n                    <button class=\"[ c-icon-link c-detail__close ]\" data-disclosure-toggle=\"expertise-nitric-oxide-donation\" data-close-details>\n\n                        <span class=\"c-icon-link__text\">\n                            Fermer\n                        <\/span>\n\n                        <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                            <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 73 73\">\n  <path d=\"M36.5 2c-4.7 0-9.2.9-13.4 2.7-4.1 1.7-7.8 4.2-11 7.4s-5.7 6.9-7.4 11C2.9 27.4 2 31.9 2 36.5s.9 9.2 2.7 13.4c1.7 4.1 4.2 7.8 7.4 11s6.9 5.7 11 7.4c4.3 1.8 8.8 2.7 13.4 2.7s9.2-.9 13.4-2.7c4.1-1.7 7.8-4.2 11-7.4s5.7-6.9 7.4-11c1.8-4.3 2.7-8.8 2.7-13.4s-.9-9.2-2.7-13.4c-1.7-4.1-4.2-7.8-7.4-11s-6.9-5.7-11-7.4C45.7 2.9 41.2 2 36.5 2m0-2C56.7 0 73 16.3 73 36.5S56.7 73 36.5 73 0 56.7 0 36.5 16.3 0 36.5 0z\"\/>\n  <path d=\"M15.06 55.774l39.951-39.951 1.415 1.414-39.952 39.951z\"\/>\n  <path d=\"M14.989 17.236l1.414-1.415 39.951 39.952-1.414 1.414z\"\/>\n<\/svg>\n                        <\/span>\n\n                    <\/button>\n\n                    <div>\n\n                        \n                            <h2 class=\"[ c-detail__title ] [ u-color-grey-2 u-text-plus-1 sm:u-text-plus-2 u-weight-bold ]\">\n                                Lib\u00e9ration d&rsquo;oxyde nitrique\n                            <\/h2>\n\n                        \n                        \n                            <span class=\"[ c-detail__subtitle ] [ u-color-white u-text-plus-1 sm:u-text-plus-2 u-weight-bold ]\">\n                                L\u2019expertise de Nicox\n                            <\/span>\n\n                        \n                    <\/div>\n\n                <\/header>\n\n                <div class=\"[ c-detail__body ] [ u-text-minus-2 ]\">\n\n                    <hr class=\"[ c-product__divider ] [ u-gap-top-plus-3 u-color-grey-3 ]\">\n\n                    <div class=\"u-color-grey-2\">\n\n                        <p>Nicox a concentr\u00e9 ses efforts en mati\u00e8re de recherche sur des pathologies oculaires dans lesquelles l\u2019oxyde nitrique (NO) pourrait jouer un r\u00f4le majeur, notamment la r\u00e9duction de la pression intraoculaire (PIO) dans le glaucome ou la sant\u00e9 r\u00e9tinienne.<\/p>\n<p>Le NO est une petite mol\u00e9cule messager naturelle bien connue qui cible une enzyme intracellulaire, la Guanylate Cyclase soluble (GCs), qui convertit la guanosine triphosphate en un second messager la guanosine monophosphate cyclique (GMPc). La voie de signalisation NO\/GCs joue un r\u00f4le cl\u00e9 dans la r\u00e9gulation de l\u2019hom\u00e9ostasie de la PIO et du flux sanguin oculaire. L\u2019augmentation, stimul\u00e9e par le NO, de la concentration en GMPc dans le r\u00e9seau trab\u00e9culaire conduit \u00e0 la s\u00e9questration du calcium intracellulaire, \u00e0 la relaxation de ce r\u00e9seau trab\u00e9culaire et, par cons\u00e9quent \u00e0 l\u2019augmentation du flux d\u2019humeur aqueuse sortant du segment ant\u00e9rieur de l\u2019\u0153il par la voie de drainage primaire ou conventionnelle. Tous les m\u00e9canismes pr\u00e9c\u00e9demment d\u00e9crits pourraient conduire \u00e0 la r\u00e9duction de la PIO et \u00e0 l\u2019am\u00e9lioration de la perfusion oculaire.<\/p>\n<p>L\u2019effet du NO dans les yeux pourrait \u00eatre intensifi\u00e9 et prolong\u00e9 par les inhibiteurs de la phosphodiest\u00e9rase 5 (PDE-5) qui inhibent la d\u00e9gradation de la GMPc.\u00a0 Sur la base de cet effet, nous avons cr\u00e9\u00e9 une nouvelle classe de mol\u00e9cules, les inhibiteurs de PDE-5 donneurs de NO, qui ont le potentiel d\u2019\u00eatre d\u00e9velopp\u00e9s dans les maladies de la r\u00e9tine et un candidat de cette classe est en cours d\u2019\u00e9valuation non clinique dans le traitement du glaucome ainsi que dans les maladies de la r\u00e9tine.<\/p>\n\n\n                    <\/div>\n\n                <\/div>\n\n            <\/div>\n\n        <\/div>\n\n    <\/div>\n\n<\/section>\n\n\n<section class=\"[ c-publications c-wrapper ] [  ]\">\n\n    <div class=\"c-block-anchor\" id=\"publications\"><\/div>\n\n    <div class=\"c-container\">\n\n        <hr>\n\n                \n            <h2 class=\"c-publications__title ] [ u-text-plus-1 md:u-text-plus-2 u-weight-bold ]\">\n                Publications\n            <\/h2>\n        \n        \n        \n            <div class=\"[ c-accordion ] [ u-gap-top-plus-4 ]\">\n\n                \n                    <button class=\"[ c-accordion__title ] [ u-caps u-color-blue-55 u-text-base sm:u-text-plus-1 u-weight-light ]\" data-disclosure-toggle=\"publication-ncx-470\">\n\n                        NCX 470\n\n                        <span class=\"[ c-accordion__label ] [ u-text-minus-2 ]\">\n                            <span class=\"c-icon c-accordion__icon\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 9.4 6.1\">\n  <path d=\"M4.7 6.1L0 1.4 1.4 0l3.3 3.3L8 0l1.4 1.4z\" data-name=\"Path 36\"\/>\n<\/svg>\n                            <\/span>\n                        <\/span>\n\n                    <\/button>\n\n                \n                <div class=\"[ c-accordion__panel ] [ u-links-plain ]\" data-disclosure-target=\"publication-ncx-470\">\n\n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Aqueous Humor Dynamics Of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/AHD-of-NCX470-20260210.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                United States Subgroup of the Denali Trial: A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/AGS-2026-Denali-US-poster-02092026-PDF.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension: The DENALI Trial\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/AGS-Denali-Asrani-02102026-Final.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC Trial\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Fechtner-AGS-2025-11Feb2025-1.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                A phase 3 adaptive dose selection trial of NCX 470, a nitric oxide-donating bimatoprost for open-angle glaucoma or ocular hypertension: The MONT BLANC study\n                            <\/h3>\n\n                        \n                        \n                        \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S1551714424003136?via%3Dihub\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n\n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork\/Schlemm&rsquo;s Canal Constructs\n                            <\/h3>\n\n                        \n                        \n                        \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38088745\/\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n\n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study\n                            <\/h3>\n\n                        \n                        \n                        \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.ajo.com\/article\/S0002-9394(24)00095-3\/abstract\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n\n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Intraocular Pressure Reduction with NCX 470 versus Latanoprost In Previously Treated Versus Treatment-Na\u00efve Patients\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/AGS-2024-_-Mansberger-poster.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Intraocular Pressure Reduction with NCX 470 versus Latanoprost Across the Spectrum of Baseline Intraocular Pressures\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/AGS-2024-_-Fechtner-poster.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork\/Schlemm\u2019s Canal Constructs\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Galli-et-al_2023_JOPT.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia\/Reperfusion Injury of Optic Nerve Head and Retina\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Sgambellone-et-al.-TVST_2023.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 470, a Nitric Oxide Donating Bimatoprost versus Latanoprost Has Greater Proportion of Subjects Achieving \u226510 mmHg IOP Decrease in Phase 3 Trial\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/WGC-Fechtner-FINAL-clean.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 470, a Nitric Oxide Donating Bimatoprost Compared with Latanoprost &#8211; Adaptive Design Period Results from the Phase 3 Mont Blanc Clinical Trial\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/WGC-Mansberger-Final-clean.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Effects of NCX 470, a nitric oxide (NO)-donating bimatoprost, in an in vitro 3D-human trabecular meshwork (TM)\/Schlemm&rsquo;s canal (SC) tissue model\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Galli-et-al_WGC_Final.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 470, a Nitric Oxide Donating Bimatoprost, Demonstrates Non-inferiority to Latanoprost in Phase 3 Mont Blanc Clinical Trial\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/1920_1080-poster2_21_23_Revised-Final.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 470 Restores Ocular Hemodynamics and Retinal Cell Physiology After ET-1-Induced Ischemia\/Reperfusion Injury of Optic Nerve and Retina in Rabbits\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Bastia_JOPT_2022.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 470, a nitric oxide (NO)-donating prostaglanding analog, elicits sustained IOP-lowering and modifies aqueous humor dynamic in non-human primates\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Bastia-et-al_ARVO-2022-003.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 470, a nitric oxide (NO)-donating prostaglandin analog, restores ocular hemodynamics and photoreceptor function after endothelin-1-induced ischemia\/reperfusion injury in rabbits\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Impagnatiello-et-al_ARVO-2022_FINAL.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042% and 0.065%) and Latanoprost 0.005% in Patients with Open-Angle Glaucoma or Ocular Hypertension: The Dolomites Study\n                            <\/h3>\n\n                        \n                        \n                        \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/journals.lww.com\/glaucomajournal\/Abstract\/9900\/A_Randomized,_Controlled_Comparison_of_NCX_470.6.aspx\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n\n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma Francesco Impagnatiello; Elena Bastia; Nicoletta Almirante; Stefania Brambilla; Brigitte Duquesroix; Angela C Kothe; Michael V W Bergamini\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Impagnatiello-2019-BJP.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                 NCX 470, a nitric oxide (NO)-donating bimatoprost lowers intraocular pressure in rabbits, dogs and non-human primate models of glaucoma Francesco Impagnatiello; Elena Bastia; Carol B Toris; Achim H Krauss; Ganesh Prasanna; Ennio Ongini Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):5809. doi\n                            <\/h3>\n\n                        \n                        \n                        \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"http:\/\/arvojournals.org\/article.aspx?articleid=2335881&#038;resultClick=1\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n\n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                 Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical models. Impagnatiello F, Toris CB, Batugo M, Prasanna G, Borghi V, Bastia E, Ongini E, Krauss AH. Invest Ophthalmol Vis Sci. 2015;56(11):6558-64. http:\/\/iovs.arvojournals.org\/article.aspx?articleid=2461805\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/i1552-5783-56-11-6558-2.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                                    \n                <\/div>\n            \n            <\/div>\n        \n        \n            <div class=\"[ c-accordion ] [ u-gap-top-plus-4 ]\">\n\n                \n                    <button class=\"[ c-accordion__title ] [ u-caps u-color-blue-55 u-text-base sm:u-text-plus-1 u-weight-light ]\" data-disclosure-toggle=\"publication-vyzulta\">\n\n                        VYZULTA\n\n                        <span class=\"[ c-accordion__label ] [ u-text-minus-2 ]\">\n                            <span class=\"c-icon c-accordion__icon\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 9.4 6.1\">\n  <path d=\"M4.7 6.1L0 1.4 1.4 0l3.3 3.3L8 0l1.4 1.4z\" data-name=\"Path 36\"\/>\n<\/svg>\n                            <\/span>\n                        <\/span>\n\n                    <\/button>\n\n                \n                <div class=\"[ c-accordion__panel ] [ u-links-plain ]\" data-disclosure-target=\"publication-vyzulta\">\n\n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review. Constance O Okeke, Nora Lee Cothran, Desirae A Brinkley, Kamran Rahmatnejad,Frank J Rodi\u00f1o, James E Deom \n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/OPTH-442940-latanoprostene-bunod-0-024-in-patients-with-open-angle-glau.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Latanoprostene Bunod 0.024% in Subjects With Open-angle Glaucoma or Ocular Hypertension: Pooled Phase 3 Study Findings Robert N. Weinreb, Jeffrey M. Liebmann, Keith R. Martin, Paul L. Kaufman,Jason L. Vittitow\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Weinreb-J-Glaucoma-2018-Pooled-phase-3-1.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension The APOLLO Study. Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Ophthalmol. 2016;123:965-73.\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/PIIS0161642016000646-2.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: The LUNAR Study. http:\/\/www.ajo.com\/article\/S0002-9394(16)30223-9\/pdf Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Am J Ophthalmol. 2016;168:250\u20139.\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/PIIS0002939416302239-1.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study Kazuhide Kawase, Jason L. Vittitow, Robert N. Weinreb, Makoto Araie For the JUPITER Study Group\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Kawase-Advances-in-Therapy-2016-JUPITER.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours JOHN H.K. LIU, JOHN R. SLIGHT, JASON L. VITTITOW, BALDO SCASSELLATI SFORZOLINI, ROBERT N. WEINREB\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Liu-Am-J-Ophthalmol-2016-CONSTELLATION.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24h in Healthy Japanese Subjects Makoto Araie, Baldo Scassellati Sforzolini, Jason Vittitow, Robert N. Weinreb\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Araie-Advances-in-Therapy-2015-KRONUS.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL; VOYAGER study group. Br J Ophthalmol. 2015;99(6):738-45.\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/738.full_.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                 Regulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunod. Cavet ME, Vollmer TR, Harrington KL, VanDerMeid K, Richardson ME. Invest Ophthalmol Vis Sci. 2015;56(6):4108-16. http:\/\/iovs.arvojournals.org\/article.aspx?articleid=2363039\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/i1552-5783-56-6-4108.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2\u03b1 agonist, in preclinical models. Krauss AH, Impagnatiello F, Toris CB, Gale DC, Prasanna G, Borghi V, Chiroli V, Chong WK, Carreiro ST, Ongini E. Exp Eye Res. 2011;93(3):250-5. \n                            <\/h3>\n\n                        \n                        \n                        \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/doi.org\/10.1016\/j.exer.2011.03.001\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n\n                        \n                                    \n                <\/div>\n            \n            <\/div>\n        \n        \n            <div class=\"[ c-accordion ] [ u-gap-top-plus-4 ]\">\n\n                \n                    <button class=\"[ c-accordion__title ] [ u-caps u-color-blue-55 u-text-base sm:u-text-plus-1 u-weight-light ]\" data-disclosure-toggle=\"publication-inhibiteurs-de-la-phosphodiesterase-5-pde-5-donneurs-de-no\">\n\n                        Inhibiteurs de la phosphodiest\u00e9rase-5 (PDE-5) donneurs de NO \n\n                        <span class=\"[ c-accordion__label ] [ u-text-minus-2 ]\">\n                            <span class=\"c-icon c-accordion__icon\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 9.4 6.1\">\n  <path d=\"M4.7 6.1L0 1.4 1.4 0l3.3 3.3L8 0l1.4 1.4z\" data-name=\"Path 36\"\/>\n<\/svg>\n                            <\/span>\n                        <\/span>\n\n                    <\/button>\n\n                \n                <div class=\"[ c-accordion__panel ] [ u-links-plain ]\" data-disclosure-target=\"publication-inhibiteurs-de-la-phosphodiesterase-5-pde-5-donneurs-de-no\">\n\n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                 NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys Elena Bastia 1, Carol Toris 2, Jean-Michel Bukowski 3, Stefania Brambilla 1, Corinna Galli 1, Nicoletta Almirante 1, Michael V W Bergamini 4, Laura Lucarini 5, Tomas Navratil 6, Francesco Impagnatiello 1  https:\/\/pubmed.ncbi.nlm.nih.gov\/33595367\/\n                            <\/h3>\n\n                        \n                        \n                        \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/33595367\/\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n\n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma Impagnatiello F., Bastia E., Toris C., Fan S., Brambilla S., Galli C., Almirante N., Bergamini M.V.W.\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Impagnatiello_ARVO-2019_03272019.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                 Intraocular pressure (IOP) reduction elicited with NCX 1741, a dual acting nitric oxide (NO) and phosphodiesterase type-5 (PDE5) inhibitor or travoprost in a non-human primate model of ocular hypertension and glaucoma Impagnatiello F., Navratil T., Toris C.B., Bergamini M.V.W., et al. https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2767712 https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2767712\n                            <\/h3>\n\n                        \n                        \n                        \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2767712\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n\n                        \n                                    \n                <\/div>\n            \n            <\/div>\n        \n        \n            <div class=\"[ c-accordion ] [ u-gap-top-plus-4 ]\">\n\n                \n                    <button class=\"[ c-accordion__title ] [ u-caps u-color-blue-55 u-text-base sm:u-text-plus-1 u-weight-light ]\" data-disclosure-toggle=\"publication-composes-donneurs-de-no\">\n\n                        Compos\u00e9s donneurs de NO\n\n                        <span class=\"[ c-accordion__label ] [ u-text-minus-2 ]\">\n                            <span class=\"c-icon c-accordion__icon\">\n                                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 9.4 6.1\">\n  <path d=\"M4.7 6.1L0 1.4 1.4 0l3.3 3.3L8 0l1.4 1.4z\" data-name=\"Path 36\"\/>\n<\/svg>\n                            <\/span>\n                        <\/span>\n\n                    <\/button>\n\n                \n                <div class=\"[ c-accordion__panel ] [ u-links-plain ]\" data-disclosure-target=\"publication-composes-donneurs-de-no\">\n\n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                 NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGF\u03b22-Induced Outflow in HTM\/HSC Constructs Elena Bastia,Carol B.Toris, Stefania Brambilla,Corinna Galli, Nicoletta Almirante,Michael V. W. Bergamini, Emanuela Masini, Silvia Sgambellone, Andrea M. Unser, Feryan Ahmed, Karen Y. Torrejon, Tomas Navratil, and Francesco Impagnatiello\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Bastia_IOVS_2021-1.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 667, a novel nitric oxide (NO) donor lowers intraocular pressure (IOP) via stimulation of trabecular meshwork\/Schlemm\u2019s canal outflow facility Impagnatiello F, Bastia E, Torrejon KY, Unser AM, Ahmed F. ARVO 2018, Honolulu, Hawaii, USA\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Impagnatiello-et-al_ARVO-2018_poster-final.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Repeated dosing of NCX 667, a new nitric oxide (NO) donor, retains IOP-lowering activity in animal models of glaucoma. Bastia E, Impagnatiello F, Ongini E, Serle JB, Bergamini MVW. Invest Ophthalmol Vis Sci. 2017;58(8):2106. ARVO 2017, Baltimore, Maryland, USA\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Bastia_ARVO-2017.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                IOP-lowering effects of NCX 667 in combination with travoprost in ocular normotensive and transient hypertensive rabbits. Bastia E, Masini E, Durante M, Bergamini MVW., Ongini E, Impagnatiello F. Invest Ophthalmol Vis Sci. 2016;57(12):3031. ARVO 2016, Seattle, Washington, USA\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Bastia_ARVO_2016-1.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                NCX 667, a novel nitric oxide (NO) donor lowers intraocular pressure (IOP) via stimulation of trabecular meshwork\/Schlemm\u2019s canal outflow facility Impagnatiello F, Bastia E, Torrejon KY, Unser AM, Ahmed F. ARVO 2018, Honolulu, Hawaii, USA\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/Impagnatiello-et-al_ARVO-2018_poster-final.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                    \n                        \n                        \n                            <h3 class=\"[ c-publications__name ] [ u-gap-top-plus-3 u-text-base u-weight-bold ]\">\n                                Nitric oxide (NO): an emerging target for glaucoma. Cavet ME, Vittitow JL, Impagnatiello F, Ongini E, Bastia E. Invest Ophthalmol Vis Sci. 2014;55(8):5005-15.\n                            <\/h3>\n\n                        \n                        \n                                            \n                            <p class=\"[ c-publications__read-more ] [ u-gap-top-half ]\">\n                                <a class=\"c-icon-link\" href=\"https:\/\/www.nicox.com\/wp-content\/uploads\/i1552-5783-55-8-5005.pdf\" data-variant=\"medium\" target=\"_blank\">\n                                    <span class=\"c-icon-link__text\">Pour plus d&rsquo;informations<\/span>\n                                    <span class=\"c-icon c-icon-link__icon\" aria-hidden=\"true\">\n                                        <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 72.3 36.2\">\n  <path d=\"M54.2 0l-1.4 1.4 15.7 15.7H0v2h68.4L52.8 34.7l1.4 1.5 18.1-18.1z\"\/>\n<\/svg>\n                                    <\/span>\n                                <\/a>\n                            <\/p>\n                        \n                        \n                                    \n                <\/div>\n            \n            <\/div>\n        \n        \n    <\/div>\n\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-10661","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Portefeuille et domaines th\u00e9rapeutiques - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Portefeuille et domaines th\u00e9rapeutiques - Nicox\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-24T06:36:33+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/portefeuille-de-therapeutiques-ophtalmiques\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/portefeuille-de-therapeutiques-ophtalmiques\\\/\",\"name\":\"Portefeuille et domaines th\u00e9rapeutiques - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2021-08-03T08:34:38+00:00\",\"dateModified\":\"2026-02-24T06:36:33+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/portefeuille-de-therapeutiques-ophtalmiques\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Portefeuille et domaines th\u00e9rapeutiques - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/","og_locale":"fr_FR","og_type":"article","og_title":"Portefeuille et domaines th\u00e9rapeutiques - Nicox","og_url":"https:\/\/www.nicox.com\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/","og_site_name":"Nicox","article_modified_time":"2026-02-24T06:36:33+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/","url":"https:\/\/www.nicox.com\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/","name":"Portefeuille et domaines th\u00e9rapeutiques - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2021-08-03T08:34:38+00:00","dateModified":"2026-02-24T06:36:33+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/portefeuille-de-therapeutiques-ophtalmiques\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/pages\/10661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=10661"}],"version-history":[{"count":9,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/pages\/10661\/revisions"}],"predecessor-version":[{"id":18431,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/pages\/10661\/revisions\/18431"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=10661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}